Literature DB >> 11698296

Reconstitution of bactericidal activity in chronic granulomatous disease cells by glucose-oxidase-containing liposomes.

C E Gerber1, G Bruchelt, U B Falk, A Kimpfler, O Hauschild, S Kuçi, T Bächi, D Niethammer, R Schubert.   

Abstract

Chronic granulomatous disease (CGD) is an inherited primary immunodeficiency characterized by phagocytes devoid of a functioning nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. The failure of CGD phagocytes to produce reactive oxygen species (ROS) results in a marked increase in the susceptibility of affected patients to life-threatening bacterial and fungal infections. This study investigated whether loading of CGD phagocytes with glucose oxidase (GO)-containing liposomes (GOLs) could restore cellular production of bactericidal ROS (eg, H2O2 and HOCl) in vitro. Results indicate that GO encapsulated in liposomes enabled NADPH oxidase-deficient phagocytes to use H2O2 for the production of highly bactericidal HOCl. The intracellular colocalization of bacteria and liposomes (or liposome-derived ferritin) was demonstrated by confocal laser microscopy and electron microscopy. After uptake of GOLs (approximately 0.2 U/mL at 1 mM total lipid concentration, size approximately 180 nm), CGD granulocytes produced HOCl levels comparable to those of normal phagocytes. Remarkably, after treatment with GOLs, CGD phagocytes killed Staphylococcus aureus as efficiently as normal granulocytes. Moreover, treated cells retained sufficient motility toward chemotactic stimuli as measured by chemotaxis assay. Side effects were evaluated by measuring the H2O2 concentrations and the production of methemoglobin in whole blood. These studies revealed that H2O2 produced by GOLs was degraded immediately by the antioxidative capacity of whole blood. Elevated methemoglobin levels were observed only after application of extremely high amounts of GOLs (2 U/mL). In summary, the application of negatively charged GOLs might provide a novel effective approach in the treatment of patients with CGD at high risk for life-threatening infections.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698296     DOI: 10.1182/blood.v98.10.3097

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Insights into primary immune deficiency from quantitative microscopy.

Authors:  Emily M Mace; Jordan S Orange
Journal:  J Allergy Clin Immunol       Date:  2015-06-13       Impact factor: 10.793

Review 2.  Pondering neutrophil extracellular traps with healthy skepticism.

Authors:  William M Nauseef; Paul Kubes
Journal:  Cell Microbiol       Date:  2016-08-23       Impact factor: 3.715

Review 3.  How neutrophils kill microbes.

Authors:  Anthony W Segal
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

Review 4.  Myeloperoxidase: a front-line defender against phagocytosed microorganisms.

Authors:  Seymour J Klebanoff; Anthony J Kettle; Henry Rosen; Christine C Winterbourn; William M Nauseef
Journal:  J Leukoc Biol       Date:  2012-10-11       Impact factor: 4.962

Review 5.  NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.

Authors:  Becky A Diebold; Susan M E Smith; Yang Li; J David Lambeth
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

6.  Staphylococcus aureus SaeR/S-regulated factors reduce human neutrophil reactive oxygen species production.

Authors:  Fermin E Guerra; Conrad B Addison; Nienke W M de Jong; Joseph Azzolino; Kyler B Pallister; Jos A G van Strijp; Jovanka M Voyich
Journal:  J Leukoc Biol       Date:  2016-06-22       Impact factor: 4.962

Review 7.  Neutrophil-generated oxidative stress and protein damage in Staphylococcus aureus.

Authors:  William N Beavers; Eric P Skaar
Journal:  Pathog Dis       Date:  2016-06-27       Impact factor: 3.166

Review 8.  Neutrophils: Between host defence, immune modulation, and tissue injury.

Authors:  Philipp Kruger; Mona Saffarzadeh; Alexander N R Weber; Nikolaus Rieber; Markus Radsak; Horst von Bernuth; Charaf Benarafa; Dirk Roos; Julia Skokowa; Dominik Hartl
Journal:  PLoS Pathog       Date:  2015-03-12       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.